indication

Schizo Affective Disorder

Competitive landscape projected to naltrexone and bupropion (combination)’s launch window

as of 2026-07-01
Competitive set
4
4 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
36 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
naltrexone and bupropion (combination) launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 43 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 11 trial
OwnerJohnson & Johnson
Protection2041
drugRecruiting
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 41 trial
OwnerIntra-Cellular Therapies, Inc.
Protection2040
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—

Market size

prevalence as a range, not a number